INTRODUCTION
Each year approximately 16,000 individuals in the U.S. are diagnosed with CLL. 1 Although classified as a low-grade lymphoproliferative disorder, 2-10% CLL patients will experience transformation to a more aggressive lymphoma during the course of their disease, with a transformation rate of 0.5-1% per year. [2] [3] [4] [5] [6] [7] The first description of transformation was proposed by Maurice Richter in his seminal 1928 paper describing the pathologic appearance of a "generalized reticular cell sarcoma" in a patient with
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From CLL. 8 Forty years later, Lortholary et al introduced the term "Richter Syndrome" (RS) to describe DLBCL occurring in CLL patients. 9 The 2008 World Health Classification of hematopoietic tumors defines RS as the transformation of CLL into a more aggressive lymphoma. 10 The vast majority of these transformations are DLBCL; although rarely, transformation to Hodgkin lymphoma (HL) is documented. According to the Hans-Choi algorithm (based on immunohistochemistry), 11 90-95% of DLBCL transformations in patients with CLL are of the more aggressive activated B-cell subtype (ABC). 5, 12 Recent studies have sub-categorized DLBCL arising in the context of CLL as either: (1) DLBCL that is "clonally related" to CLL (representing ~80% of cases) or (2) development of DLBCL that is "clonally unrelated" to the underlying CLL (remaining 20% cases). 5, 12 As discussed below, the distinction between these entities has critical implications for both prognosis and management.
The rubric "Richter Syndrome" has also been used to describe transformation of other low-grade B-cell lymphoproliferative disorders to an aggressive lymphoma. 13 The rate of transformation to DLBCL in such patients varies by histology, occurring in 11-30% of patients with in follicular lymphoma (~ 2-3% risk per year), 14, 15 13% of patients with lymphoplasmacytic lymphoma, 16 and 11% of those with splenic marginal zone lymphoma. 17 Since the biology and risk factors for transformation vary by histologic subtype, this review is primarily focused on the approach to the diagnosis and management of RS in patients with CLL.
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HOW COMMON IS RICHTER SYNDROME IN CLL PATIENTS?
Several retrospective studies have estimated the prevalence of RS in CLL patients ranges from 1-11% (Table 1) . 2, 4, 7, [18] [19] [20] [21] The large variation in prevalence in these historical series is due to heterogeneity in the patient populations studied, varying length of follow-up, how aggressively biopsies were pursed in patients with rapidly progressive lymphadenopathy, and whether or not the analysis was restricted to biopsy proven cases or included individuals with "clinically suspected" transformation. 7 Although the incidence of RS among CLL patients in specific clinical trials have also been reported, [22] [23] [24] [25] these rates must be interpreted with caution since they are derived from selected CLL patients who progressed to require treatment, fit the eligibility criteria for trial participation, and where the therapy used may have influenced the risk of transformation. More accurate estimations of the risk transformation can be derived from prospective cohort studies of newly diagnosed CLL patients. In our study of all newly diagnosed CLL patients seen at Mayo Clinic from 2000 -2011, 37/1641 (2.3%) patients developed biopsy-proven RS at a rate of 0.5%/year. 2 Nearly half of these patients (n=17; 46%) experienced RS prior to requiring treatment for CLL. 2 A common misperception is that RS in CLL patients is a late event, and that the majority of cases do not occur until 5-10 years after CLL diagnosis. 26 Studies that report the median time to occurrence of RS challenge this notion, with a median time from CLL diagnosis to RS of 1.8-5 years. 27 WHO DEVELOPS RICHTER SYNDROME?
Germline genetic characteristics, clinical characteristics, biologic and genetic features of the CLL B-cell clone, and therapy for progressive CLL influence the risk of RS ( Figure 1 ).
Inherited Predisposition to Richter Syndrome
Heritable germline polymorphisms may predispose certain individuals who develop CLL to later experience transformation. Specifically, germline polymorphisms in B-cell lymphoma 2 (BCL-2; rs4987852), 28 CD38 (rs6449182), 29 and low-density lipoprotein receptor-related protein 4 (LRP4; rs2306029) 30 genes have been reported to confer increased risk of RS. The precise functional consequences of these germline polymorphisms in the pathogenesis of RS remain to be elucidated.
Clinical and Laboratory Features at CLL Diagnosis
Advanced Rai stage (III-IV) at CLL diagnosis and lymph nodes >3 cm on physical examination are the only clinical features associated with a higher risk of future RS. 2, 3, 6, 20 Other clinical features commonly used to predict CLL progression including Although specific IGHV family usage, IGHV 4-39, was reported to be associated with a higher risk of RS; 21 this observation was not confirmed in other studies. 2, 33 Other biologic characteristics of the leukemic B-cell that are associated with the risk of CLL progression such as ZAP-70 status, CD38 status, and CD49d status have also been found to be associated with risk of future RS. 2, 5, 20 Shorter telomere length, which is a marker of genetic instability, is also associated with increased risk of RS.
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Whether the associations between these biologic characteristics of CLL B-cells are mechanistically involved in RS or are simply markers of patients who are more likely to acquire genetic events that lead to RS is not yet determined.
Somatic Genetic Characteristics
Early studies suggested that FISH detectable genetic abnormalities associated with more aggressive CLL (i.e. del(11q23.1) and del(17p13.1)), are also associated with In another recent paper, Fabbri and colleagues reported similar observations using whole-exome sequencing to compare the CLL-phase and RS-phase of 9 patients with RS. 
CLL Therapy and Transformation Risk
Although the link between CLL therapy and subsequent myelodysplasia is well established, 44 the link between CLL treatment and RS is less clear. In a cohort study of 1641 newly diagnosed CLL patients seen at Mayo Clinic and followed prospectively, the rate of transformation increased from 0.5% per year prior to therapy to 1% per year after receiving treatment for CLL. 2 Specifically, the risk of RS increased three-fold (odds ratio=3.26; p=0.0003) among patients who received the combination of alkylating agents (which induce DNA damage) and purine nucleoside analogues (which impair DNA repair), but did not increase for those who received only one of these drug classes.
In contrast, in the Cancer and Leukemia Group B (CALGB) 9011 study that compared fludarabine and chlorambucil monotherapy to fludarabine and chlorambucil in combination, no difference in the 10-year rate of transformation was observed between treatment arms (7% fludarabine monotherapy, 5% chlorambucil monotherapy, and 8% combination arm). 25 Similarly, after a median follow-up of 3.5 years, there was no difference in the rates of RS in patients treated with either chlorambucil alone (2%), fludarabine alone (1%) or the combination of fludarabine and cyclophosphamide (1%) in the UK CLL4 trial. 22 Thus, the impact of conventional CLL therapy alone or in combination on risk of RS is unclear at this time.
Although novel agents such as ibrutinib (a Bruton's tyrosine kinase inhibitor) and idelalisib (a phosphatidylinositide 3-kinase δ inhibitor) have shown remarkable efficacy in CLL, little is known about their relationship to RS. [45] [46] [47] In a report on 85 heavily pretreated patients with relapsed/refractory CLL who were treated with ibrutinib, 7(8%) patients developed RS. 46 Many of these events developed shortly after starting therapy 1 1 suggesting unrecognized RS likely predated initiation of ibrutinib treatment. Extended follow-up among larger cohorts of CLL patients will be necessary to fully understand the risk of RS in CLL patients treated with these therapeutic agents.
Immunosuppression and Richter Syndrome
Infection with Epstein-Barr virus (EBV), detected by staining for latent membrane protein 1 (LMP1) or by in situ hybridization of EBV-encoded RNA transcripts, has been reported in 0-15% of RS tissue samples. 2, 5, 7, 20, 48 Whether the EBV is causative in the disease process of RS in these patients or is merely a manifestation of the underlying immunosuppressed state associated with CLL is incompletely understood. Several cases of EBV-positive aggressive lymphomas following T-cell depleting therapies such as alemtuzumab have also been described in CLL patients. [49] [50] [51] This type of alemtuzumab-associated aggressive lymphoma is typical clonally unrelated to the underlying CLL, and thus it is debatable whether or not to consider such events true RS.
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HOW DO WE DIAGNOSE RICHTER SYNDROME?
Our diagnostic approach to a CLL patient with suspicion of RS is shown in Figure   2 . Although non-specific, several signs and symptoms should alert the CLL provider of a possible transformation. These include high-grade fevers, rapidly enlarging lymph nodes, weight loss, hypercalcemia, and a markedly elevated LDH. Occasionally, extranodal involvement of the central nervous system, eyes, testes and lungs can also be the presenting manifestation of RS. 53 Although they raise suspicion of RS, all of these signs and symptoms can also be due to progressive CLL, particularly after acquisition of del(17p13.1) or TP53 inactivation. value of 53% and negative predictive value of 97%. 54 This high negative predictive value is clinically useful, and reduces the post-test probability of RS in patients without FDG-avid lymphadenopathy to ~3%. In contrast, the low positive predictive value of PET/CT makes it essential to perform tissue biopsy in patients with FDG-avid lymphadenopathy since only half of these patients will have RS on biopsy. The etiology of the FDG-avid tissue in the remaining patients is most often due to progressive CLL, other malignancies, and infectious or inflammatory conditions. 55 Other studies have confirmed an SUV threshold of 5 on PET/CT to identify CLL patients with clinically suspected RS who require tissue biopsy. 56, 57 Once the optimal site for biopsy is identified, the optimal type of biopsy must be
determined. An excisional lymph node biopsy is considered the gold standard for the diagnosis of RS and should be pursued in all patients with a rapidly enlarging or FDGavid lesion that is readily amenable to excisional biopsy. For patients whose only sites WHAT IS THE PROGNOSIS OF RICHTER SYNDROME?
The 
WHAT ARE THE TREATMENT OPTIONS FOR PATIENTS WITH RICHTER SYNDROME?

Conventional Chemotherapy Approaches
Unfortunately, there are no randomized clinical trials to guide therapy for patients with RS, and thus the vast majority of evidence to guide practice is derived from singlearm phase 2 studies (Table 2) . Traditionally, treatment regimens commonly used to treat other B-cell Non-Hodgkin lymphomas have been used to treat CLL patients with RS. 48, 62, 63 Anthracycline-based therapy (most commonly R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone]) has been the historical 1 7 standard treatment for DLBCL, 64 and has also been the traditional approach in patients with follicular lymphoma who experience histologic transformation to a more aggressive lymphoma. [65] [66] [67] Based in large part on extrapolation of this data, CHOP (and more recently R-CHOP) has been the initial treatment approach for CLL patients who experience RS. The efficacy of R-CHOP in CLL patients with RS was first prospectively evaluated in the CLL2G trial of the German CLL study group which enrolled 15 patients with RS. Although only 7% of patients achieved a CR, the overall response rate (ORR) was 67% and the median overall survival (OS) was 27 months. Treatment-related mortality was low (3%). 68 In a retrospective series of 12 RS patients treated with R-CHOP at MD Anderson Cancer Center, the ORR was 50% and the median OS was 15 months. 69 Other trials have explored alternative anthracycline-based regimens to try and improve efficacy. In a phase 2 study of 29 RS patients treated with hyperCVXD regimen (fractionated cyclophosphamide, vincristine, liposomal daunorubicin and dexamethasone), the ORR was 41%, with 38% CRs and a partial response (PR) rate of 3%. Although the reported CR rate was higher than that observed in the studies of R-CHOP, the median survival with hyperCVXD was only 10 months. 70 A subsequent study of 30 patients added rituximab and granulocyte macrophage -colony stimulating factor to the hyperCVXD platform and incorporated high dose methotrexate and cytarabine every other cycle. Unfortunately, the ORR was similar to the hyperCVXD regimen and median survival was only 8.5 months. 71 Treatment related mortality with both these hyperCVXD trials exceeded 10%.
Platinum-containing regimens have also been evaluated as initial therapy in CLL patients with RS. Investigators at the MD Anderson Cancer Center tested the 1 8 combination of oxaliplatin, fludarabine, cytarabine and rituximab (OFAR) using two different dosing schedules. Among the 55 RS patients treated on both trials, the ORR ranged from 43-50% and median survival was 6-8 months. Unfortunately, the OFAR platform was associated with grade 3/4 neutropenia and thrombocytopenia occurring in approximately 80% patients under both schedules. 69, 72 Given the efficacy of purine analogs in patients with CLL, a pilot study tested the backbone of fludarabine and cytarabine in combination with either cyclophosphamide (PFA) or cisplatin (CFA) in 12 RS patients. The ORR was 45% with 18% CRs and a median survival of 17 months. 73 Based on these results, all four agents (cisplatin, fludarabine, cyclophosphamide, cytarabine) were combined in a follow-up study of 15 RS patients. The four drug combination caused profound toxicity (20% treatment-related mortality in the first 4 weeks) and only one patient (5%) achieved a response. 74 Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan was also tested in a pilot trial of 7 RS patients; however no patient responded. 75 
Novel Therapeutic Approaches
Ibrutinib has demonstrated single agent activity in a series of patients with relapsed/refractory de novo DLBCL (n=70) with an ORR of 23%. Notably, ibrutinib appeared to be more active in patients with the ABC subtype (41%) relative to those with germinal center B-cell subtype (5%, p=0.007). 76 Although ibrutinib has also shown remarkable efficacy in CLL patients, 7 (8%) of the 85 patients with relapsed/refractory CLL treated in the initial ibrutinib trial developed RS. 46 Although this information does not directly provide insight into whether ibrutinib may have clinical activity in patients with RS, it suggests ibrutinib monotherapy is not an adequate approach for many RS Other novel approaches that may have promise in the management of RS as single agents or in combination with traditional chemotherapy approaches include (BCL-2 antagonist), idelalisib and NOTCH1 inhibitors.
Role of stem cell transplantation
Given the poor response rates and survival with chemotherapy alone in RS, both group, patients who underwent SCT had an improved outcome compared to those that did not. Among those who underwent SCT, the estimated cumulative 3-year survival probability was 75% for those who were transplanted in CR or PR, compared to 21% for patients who underwent SCT as salvage therapy for relapsed/refractory RS.
Furthermore, the estimated 3-year survival probability was 27% for those patients who responded to initial chemotherapy for RS, but did not undergo subsequent SCT;
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From 0 suggesting that post-remission transplant increases the durability of remission in patients who respond to induction. relapses were related to RS (remainder were due to CLL), suggesting autologous SCT may eradicate the RS component in many patients even though the underlying CLL may persist. 78 Several other studies exploring the role of SCT in the treatment of transformed low-grade B-cell lymphoproliferative neoplasms (most commonly follicular lymphoma), have included a small proportion of patients with CLL. These studies suggest that SCT is feasible in patients with RS and may be associated with improved outcomes. 65, 67 Although all of these studies are subject to potential selection bias and are limited by the fact that the clonal relationship of the CLL and DLBCL was not determined, collectively they suggest that "fit" RS patients with limited co-morbidities
who have a donor available and demonstrate chemosensitive disease benefit from postremission SCT.
HOW WE TREAT RICHTER SYNDROME
The experience with intense combination chemotherapy-based regimens (Table   2 ) suggests that traditional chemotherapy approaches provide inadequate disease control for most patients. It is hoped that novel, targeted therapies will improve the efficacy of therapy for RS and appropriate patients should treated on well-designed clinical trials. A summary of our approach to CLL patients who develop RS and who are not treated on clinical trials is provided in Figure 4 .
The most important step in deciding the treatment plan for patients with RS is to determine if the DLBCL is clonally related to the underlying CLL. For the 20% of patients with clonally unrelated DLBCL, we recommend the use of standard therapy with R-CHOP (similar to patients with de novo DLBCL). For patients who achieve a CR, we do not pursue SCT, and recommend periodic surveillance as outlined by the National Comprehensive Cancer Network guidelines. 58 For those patients with clonally unrelated DLBCL who do not achieve a CR, salvage therapy with rituximab, ifosfamide and etoposide (RICE) or with rituximab, dexamethasone, cytarabine and cisplatin (RDHAP), followed by an autologous SCT should be considered, analogous to the approach used for patients with de novo DLBCL. 79 We favor allogeneic transplant in suitable patients with clonally unrelated DLBCL who have purine analog refractory CLL For the 80% of patients with clonally related DLBCL, our first choice of therapy is a clinical trial given the sub-optimal efficacy of the standard treatment approaches.
When a clinical trial is not available, we generally consider R-CHOP as the initial treatment option given its favorable toxicity profile, followed by consolidation with SCT. 
SPECIAL CONSIDERATIONS
Hodgkin transformation
Hodgkin transformation of CLL is a rare event and clonally unrelated to the underlying CLL in most cases. 80 At our institution, in a cohort study of 1644 newly diagnosed CLL patients followed prospectively, the prevalence of Hodgkin lymphoma (HL) after 10 years was 0.5% (~0.05%/year). 81 The median interval from CLL diagnosis to development of HL was 6. years (0-14 years). 80 In contrast to DLBCL, EBV infection in the HL tissue is present in approximately 70% of CLL patients who develop HL. 48, 80 In the Mayo series, the International Prognostic Score (IPS) for HL 82 
